Man Group plc acquired a new position in bluebird bio Inc (NASDAQ:BLUE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 82,585 shares of the biotechnology company’s stock, valued at approximately $5,041,000. Man Group plc owned approximately 0.12% of bluebird bio at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Morgan Stanley grew its position in shares of bluebird bio by 691.8% during the 1st quarter. Morgan Stanley now owns 310,752 shares of the biotechnology company’s stock valued at $14,283,000 after buying an additional 271,505 shares during the last quarter. AlphaCrest Capital Management LLC bought a new stake in shares of bluebird bio during the 1st quarter valued at about $209,000. Wells Fargo & Company MN boosted its position in shares of bluebird bio by 19.0% during the 1st quarter. Wells Fargo & Company MN now owns 225,846 shares of the biotechnology company’s stock valued at $10,380,000 after acquiring an additional 36,101 shares during the last quarter. Great Lakes Advisors LLC bought a new stake in shares of bluebird bio during the 2nd quarter valued at about $4,440,000. Finally, State Street Corp boosted its position in shares of bluebird bio by 1.4% during the 1st quarter. State Street Corp now owns 1,541,969 shares of the biotechnology company’s stock valued at $70,869,000 after acquiring an additional 20,739 shares during the last quarter. 96.39% of the stock is owned by hedge funds and other institutional investors.
Shares of bluebird bio stock opened at $53.21 on Wednesday. bluebird bio Inc has a fifty-two week low of $38.95 and a fifty-two week high of $109.58. The firm has a fifty day moving average price of $59.55 and a two-hundred day moving average price of $59.15. The company has a market cap of $3.58 billion, a PE ratio of -4.52 and a beta of 2.20.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.58) by $2.22. The firm had revenue of $198.89 million during the quarter, compared to the consensus estimate of $101.74 million. bluebird bio had a negative net margin of 272.66% and a negative return on equity of 47.02%. As a group, analysts forecast that bluebird bio Inc will post -10.42 earnings per share for the current year.
In other bluebird bio news, CEO Nick Leschly sold 431 shares of bluebird bio stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $58.60, for a total value of $25,256.60. Following the transaction, the chief executive officer now owns 99,029 shares of the company’s stock, valued at $5,803,099.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kory James Wentworth sold 596 shares of bluebird bio stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $66.38, for a total transaction of $39,562.48. Following the completion of the transaction, the insider now directly owns 9,594 shares in the company, valued at approximately $636,849.72. The disclosure for this sale can be found here. Insiders have sold a total of 1,772 shares of company stock worth $109,995 in the last three months. 3.60% of the stock is owned by insiders.
A number of brokerages have commented on BLUE. Bank of America reduced their target price on bluebird bio from $104.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Wedbush reduced their target price on bluebird bio from $89.00 to $81.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Oppenheimer started coverage on bluebird bio in a research note on Monday, August 31st. They set a “buy” rating and a $111.00 target price on the stock. BidaskClub cut bluebird bio from a “sell” rating to a “strong sell” rating in a research note on Wednesday. Finally, William Blair restated a “hold” rating on shares of bluebird bio in a research report on Sunday, August 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $101.00.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Recommended Story: How to Track your Portfolio in Google Finance
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.